MorphoSys will receive committed annual license fees, success-based development milestones, in addition to royalties on sales of marketed drug products emerging from the collaboration.
MorphoSys chief scientific officer Marlies Sproll said the HuCAL PLATINUM technology has shown potential in yielding effective therapeutics for the treatment of infectious diseases.
"We will continue to exploit this commercial opportunity within selected partnerships, including this new collaboration with ContraFect," Sproll said.
ContraFect CEO Robert Nowinski said using HuCAL to generate these antibodies was of key importance to us since this technology enables the selection of thousands of unique antibody molecules from a single library.